NRIX
Company Description
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.
Track Record
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 83.98M | 54.55M | 76.99M | 38.63M | 29.75M | 17.82M | 31.11M | 37.45M |
| Net Income | (264.46M) | (193.57M) | (143.95M) | (180.36M) | (117.19M) | (43.24M) | (21.70M) | (9.43M) |
| EPS | -3.05 | -2.88 | -2.65 | -3.71 | -2.73 | -2.76 | -0.56 | -0.59 |
| Free Cash Flow | (263.47M) | (181.86M) | (89.77M) | (172.05M) | (90.03M) | (4.63M) | (1.05M) | (33.27M) |
| FCF / Share | -3.04 | -2.71 | -1.65 | -3.54 | -2.10 | -0.30 | -0.03 | -2.07 |
| Operating CF | (249.47M) | (172.58M) | (81.36M) | (159.81M) | (84.36M) | (80,000) | 601,000 | (31.68M) |
| Total Assets | 688.13M | 669.34M | 355.60M | 416.76M | 476.77M | 396.34M | 44.05M | 45.40M |
| Total Debt | 55.73M | 28.30M | 30.61M | 11.96M | 13.04M | 0 | 0 | 0 |
| Cash & Equiv | 246.96M | 110.00M | 54.63M | 64.47M | 80.51M | 119.36M | 34.82M | 25.59M |
| Book Value | 538.75M | 526.99M | 200.49M | 303.70M | 342.30M | 290.27M | (57.71M) | (36.85M) |
| Return on Equity | -0.49 | -0.37 | -0.72 | -0.59 | -0.34 | -0.15 | N/A | N/A |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9.04M | 6.25M | 13.58M | 7.89M | 44.06M | 18.45M | 13.28M | 12.59M | 12.09M | 16.59M | 15.16M | 18.47M |
| Net Income | (89.53M) | (87.17M) | (78.22M) | (86.42M) | (43.46M) | (56.35M) | (58.55M) | (48.96M) | (44.55M) | (41.52M) | (41.96M) | (36.98M) |
| EPS | -0.81 | -0.79 | -0.82 | -1.03 | -0.52 | -0.67 | -0.75 | -0.67 | -0.71 | -0.76 | -0.77 | -0.68 |
| Free Cash Flow | (98.51M) | (72.96M) | (72.96M) | (60.10M) | (65.84M) | (64.57M) | (50.86M) | (44.52M) | (41.64M) | (44.84M) | 24.10M | (43.59M) |
| FCF / Share | -0.89 | -0.66 | -0.77 | -0.71 | -0.78 | -0.77 | -0.65 | -0.61 | -0.67 | -0.82 | 0.44 | -0.80 |
| Operating CF | (96.57M) | (71.91M) | (67.83M) | (57.38M) | (63.16M) | (61.09M) | (48.75M) | (42.18M) | (39.70M) | (41.95M) | 26.69M | (41.13M) |
| Total Assets | 535.54M | 636.13M | 688.13M | 522.47M | 591.55M | 615.04M | 669.34M | 513.60M | 511.03M | 312.67M | 355.60M | 308.19M |
| Total Debt | 58.14M | 58.66M | 55.73M | 56.49M | 51.93M | 26.62M | 28.30M | 27.14M | 28.82M | 29.16M | 30.61M | 8.00M |
| Cash & Equiv | 67.69M | 71.19M | 246.96M | 78.44M | 84.26M | 75.92M | 110.00M | 99.04M | 116.79M | 49.81M | 54.63M | 42.30M |
| Book Value | 402.63M | 480.89M | 538.75M | 372.25M | 447.60M | 480.92M | 526.99M | 376.86M | 370.69M | 168.75M | 200.49M | 233.82M |
| Return on Equity | -0.22 | -0.18 | -0.15 | -0.23 | -0.10 | -0.12 | -0.11 | -0.13 | -0.12 | -0.25 | -0.21 | -0.16 |
